trending Market Intelligence /marketintelligence/en/news-insights/trending/A34hGUE2aMWH2xAdM9pxsA2 content esgSubNav
In This List

Generex acquires 51% stake in regenerative medicine company Regentys

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Generex acquires 51% stake in regenerative medicine company Regentys

Generex Biotechnology Corp. acquired a 51% stake in Miami-based regenerative medicine company Regentys Corp., which develops treatments for patients with gastrointestinal disorders.

Miramar, Fla.-based Generex Biotechnology paid $400,000 upfront to Regentys and will give another $14.6 million in milestone payments.

Regentys' lead product, ExtraCellular Matrix Hydrogel is a nonsurgical treatment for ulcerative colitis, an inflammatory disease that causes ulcers in the digestive tract. The product works as a bandage to cover the ulcer, shielding damaged tissue from the waste flow and aiding tissue regeneration and healing.

Generex Biotechnology, which develops diagnostic solutions, delivery systems and medical technologies, recently acquired New York-based regenerative medicine company Olaregen Therapeutix Inc. and pharmacy and management services.